NDAORALTABLET, ORALLY DISINTEGRATINGPriority Review
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
gene-related peptide receptor antagonist.
Indications (1)
Loss of Exclusivity
LOE Date
Mar 25, 2039
158 months away
Patent Expiry
Mar 25, 2039